Dr. Najmuddin K. Karimjee, M.D.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical Branch at Galveston (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,593
Licensed in Texas since 1992, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: University of Texas Medical Branch at Galveston
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
TX license J2631 (first issued 1992; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- HCA Houston Healthcare Kingwood Kingwood, TX
- Tops Surgical Specialty Hospital Houston, TX
- Huntsville Memorial Hospital Huntsville, TX
- Townsen Memorial Hospital Humble, TX
- Aspire Hospital Conroe, TX
Medical groups
- Pcp for Life PA (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,593
- Services billed
- 40,291
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Injection, dexamethasone sodium phosphate, 1 mg | 4,933 | 349 |
| Established patient office or other outpatient visit, 20-29 minutes | 2,940 | 1,127 |
| Insertion of needle into vein for collection of blood sample | 1,938 | 1,052 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,507 | 730 |
| Urinalysis, manual test | 1,084 | 821 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 1,007 | 306 |
| Injection, ceftriaxone sodium, per 250 mg | 833 | 156 |
| Injection, ketorolac tromethamine, per 15 mg | 692 | 100 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 683 | 683 |
| Detection test by immunoassay with direct visual observation for influenza virus | 536 | 224 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 101 payments worth $1,749 in total to this clinician.
| AbbVie Inc. | $638 |
|---|---|
| Astellas Pharma US Inc | $258 |
| AstraZeneca Pharmaceuticals LP | $160 |
| Exact Sciences Corporation | $154 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) | $101 |
| Xeris Pharmaceuticals, Inc. | $53.85 |
| Phathom Pharmaceuticals, Inc. | $52.95 |
| Mannkind Corporation | $52.31 |
| Food and Beverage | $1,749 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $134,505 in research payments for these studies, mostly to the institutions running them.
- Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Alnylam Pharmaceuticals Inc. - A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
Teva Pharmaceuticals USA, Inc. - Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
Alnylam Pharmaceuticals Inc. - A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1)
Alnylam Pharmaceuticals Inc. - A phase 4 randomized doubleblind placebocontrolled study to evaluate the efficacy and safety of rimegepant in episodic migraine prevention with multiple dosing regimens
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.